Effects of intravenous rtPA in patients with minor stroke

References

• Feigin VL, Brainin M, Norrving B, et al. World stroke organization (WSO): global stroke fact sheet 2022. Int J Stroke. 2022;17(1):1–10. doi: 10.1177/17474930211065917.
   Web of Science ®Google Scholar
• Wang YL, Wu D, Liao X, et al. Burden of stroke in China. Int J Stroke. 2007;2(3):211–213. doi: 10.1111/j.1747-4949.2007.00142.x.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Lavallee PC, Labreuche J, T.I.o. Investigators., et al. One-Year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016;48(6):1495–1500. doi: 10.1056/NEJMoa1412981.
   Google Scholar
• Khatri P, Conaway MR, Johnston KC, I. Acute Stroke Accurate Prediction Study. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012;43(2):560–562. doi: 10.1161/STROKEAHA.110.593897.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2019;50(12):e344–e418. doi: 10.1161/STR.0000000000000211.
   PubMed Web of Science ®Google Scholar
• Romano JG, Smith EE, Liang L, et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the get with the Guidelines-Stroke registry. JAMA Neurol. 2015;72(4):423–431. doi: 10.1001/jamaneurol.2014.4354.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The european cooperative acute stroke study (ECASS). Jama. 1995;274(13):1017–1025. doi: 10.1001/jama.1995.03530130023023.
   PubMed Web of Science ®Google Scholar
• Choi JC, Jang MU, Kang K, et al. Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke. JAHA. 2015;4(1):e001306. doi: 10.1161/JAHA.114.001306.
   Google Scholar
• Khatri P, Tayama D, Cohen G, Prisms, I.S.T.C. Groups., et al. Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third international stroke trial-3: post hoc analysis. Stroke. 2015;46(8):2325–2327. doi: 10.1161/STROKEAHA.115.009951.
   PubMed Web of Science ®Google Scholar
• You S, Saxena A, Wang X, et al. Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis. Stroke Vasc Neurol. 2018;3(1):22–27. doi: 10.1136/svn-2017-000106.
   PubMedGoogle Scholar
• Khatri P, Kleindorfer DO, Yeatts SD, et al. Strokes with minor symptoms: an exploratory analysis of the national institute of neurological disorders and stroke recombinant tissue plasminogen activator trials. Stroke. 2010;41(11):2581–2586. doi: 10.1161/STROKEAHA.110.593632.
   PubMed Web of Science ®Google Scholar
• Khatri P, Kleindorfer DO, Devlin T, Jr., et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. Jama. 2018;320(2):156–166. doi: 10.1001/jama.2018.8496.
   PubMed Web of Science ®Google Scholar
• Chen HS, Cui Y, Zhou ZH, A. Investigators., et al. Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial. Jama. 2023;329(24):2135–2144. doi: 10.1001/jama.2023.7827.
   PubMed Web of Science ®Google Scholar
• Davis SM, Donnan GA, Parsons MW, E. investigators., et al. Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7(4):299–309. doi: 10.1016/S1474-4422(08)70044-9.
   PubMed Web of Science ®Google Scholar
• Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–2363.
   PubMed Web of Science ®Google Scholar
• Adams HP, Jr., Bendixen BH, Kappelle LJ, 3rd, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41. doi: 10.1161/01.str.24.1.35.
   PubMed Web of Science ®Google Scholar
• Köhrmann M, Nowe T, Huttner HB, et al. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis. 2009;27(2):160–166. doi: 10.1159/000185607.
   PubMed Web of Science ®Google Scholar
• Duan C, Xiong Y, Gu HQ, et al. Outcomes in minor stroke patients treated with intravenous thrombolysis. CNS Neurosci Ther. 2023;29(8):2308–2317. doi: 10.1111/cns.14164.
   PubMed Web of Science ®Google Scholar
• Sykora M, Krebs S, Simader F, C. Austrian Stroke Unit Registry., et al. Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1. Int J Stroke. 2022;17(1):109–119. doi: 10.1177/1747493021991969.
   PubMed Web of Science ®Google Scholar
• Romano JG, Gardener H, Campo-Bustillo I, et al. Predictors of outcomes in patients with mild ischemic stroke symptoms: maRISS. Stroke. 2021;52(6):1995–2004. doi: 10.1161/STROKEAHA.120.032809.
   PubMed Web of Science ®Google Scholar
• Greisenegger S, Seyfang L, Kiechl S, et al. Thrombolysis in patients with mild stroke: results from the Austrian stroke unit registry. Stroke. 2014;45(3):765–769. doi: 10.1161/STROKEAHA.113.003827.
   PubMed Web of Science ®Google Scholar
• Huisa BN, Raman R, Neil W, et al. Intravenous tissue plasminogen activator for patients with minor ischemic stroke. J Stroke Cerebrovasc Dis. 2012;21(8):732–736. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.009.
   PubMed Web of Science ®Google Scholar
• Nesi M, Lucente G, Nencini P, et al. Aphasia predicts unfavorable outcome in mild ischemic stroke patients and prompts thrombolytic treatment. J Stroke Cerebrovasc Dis. 2014;23(2):204–208. doi: 10.1016/j.jstrokecerebrovasdis.2012.11.018.
   PubMed Web of Science ®Google Scholar
• Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43(9):2293–2299. doi: 10.1161/STROKEAHA.112.660415.
   PubMed Web of Science ®Google Scholar
• Liberman AL, Pinto D, Rostanski SK, et al. Clinical decision-making for thrombolysis of acute minor stroke using adaptive conjoint analysis. Neurohospitalist. 2019;9(1):9–14. doi: 10.1177/1941874418799563.
   PubMed Web of Science ®Google Scholar
• Duan C, Xiong Y, Gu H, et al. Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion. CNS Neurosci Ther. 2023;29(6):1615–1623. doi: 10.1111/cns.14124.
   PubMedGoogle Scholar
• Seners P, Perrin C, Lapergue B, et al. Bridging therapy or IV thrombolysis in minor stroke with large vessel occlusion. Ann Neurol. 2020;54(10):2491–2499. doi: 10.1002/ana.25756.
   Google Scholar